Shivaani Kummar Selected Research

EZN 2968

2/2014

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shivaani Kummar Research Topics

Disease

108	Neoplasms (Cancer) 03/2024 - 05/2003
9	Lymphoma (Lymphomas) 11/2020 - 11/2009
7	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 02/2003
6	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 03/2012
6	Circulating Neoplastic Cells 01/2020 - 02/2010
5	Sarcoma (Soft Tissue Sarcoma) 12/2023 - 07/2012
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 12/2005
4	Liver Diseases (Liver Disease) 03/2024 - 07/2013
4	Diarrhea 03/2023 - 06/2011
4	Disease Progression 03/2023 - 10/2010
4	Aggressive Fibromatosis (Desmoid) 03/2023 - 01/2015
4	Triple Negative Breast Neoplasms 01/2023 - 03/2012
4	Carcinogenesis 01/2023 - 05/2008
4	Alveolar Soft Part Sarcoma 01/2023 - 06/2013
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 07/2010
4	Hypoxia (Hypoxemia) 08/2014 - 08/2011
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 03/2024 - 07/2013
3	Breast Neoplasms (Breast Cancer) 11/2023 - 06/2005
3	Nausea 03/2023 - 01/2020
3	Neutropenia 01/2023 - 04/2012
3	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2011
3	Lung Neoplasms (Lung Cancer) 01/2022 - 03/2009
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 08/2011
3	Carcinoma (Carcinomatosis) 01/2020 - 01/2016
2	Exanthema (Rash) 03/2023 - 09/2015
2	Fatigue 03/2023 - 01/2021
2	Adenocarcinoma 01/2022 - 05/2003
2	Headache (Headaches) 01/2021 - 06/2011
2	Vomiting 01/2021 - 06/2011
2	Hematologic Neoplasms (Hematological Malignancy) 08/2017 - 08/2006
2	Rare Diseases (Rare Disease) 05/2017 - 01/2016
2	Pheochromocytoma 11/2015 - 04/2013
2	Hepatocellular Carcinoma (Hepatoma) 08/2011 - 03/2010
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2023
1	Pain (Aches) 03/2023
1	Hypophosphatemia 03/2023
1	Thyroid Neoplasms (Thyroid Cancer) 04/2022
1	Leiomyosarcoma 01/2022

Drug/Important Bio-Agent (IBA)

14	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2007
12	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2023 - 06/2009
10	Proteins (Proteins, Gene)FDA Link 01/2024 - 02/2014
10	Phosphotransferases (Kinase)IBA 12/2023 - 04/2013
10	larotrectinibIBA 12/2023 - 01/2018
9	veliparibIBA 01/2021 - 06/2009
8	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2011
6	TropomyosinIBA 12/2023 - 01/2018
6	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2023 - 06/2009
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2006
6	Histone Deacetylase InhibitorsIBA 11/2019 - 08/2006
6	Sorafenib (BAY 43-9006)FDA Link 09/2015 - 07/2010
5	Poly Adenosine Diphosphate RiboseIBA 03/2012 - 06/2009
5	Topotecan (Hycamtin)FDA LinkGeneric 01/2012 - 02/2010
4	EnzymesIBA 11/2023 - 01/2012
4	cediranib (AZD2171)IBA 01/2023 - 07/2012
4	pazopanib FDA Link 12/2021 - 07/2012
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 06/2005
3	belinostatIBA 03/2024 - 07/2013
3	nirogacestatIBA 03/2023 - 01/2015
3	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2023 - 01/2015
3	NSC 724998IBA 01/2023 - 11/2015
3	entrectinibIBA 01/2022 - 10/2018
3	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 03/2009
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 12/2009
3	adavosertibIBA 01/2021 - 10/2015
3	Messenger RNA (mRNA)IBA 01/2021 - 02/2014
3	5-fluoro-2'-deoxycytidineIBA 01/2020 - 03/2015
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 11/2015 - 09/2011
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 08/2015 - 01/2010
3	Bevacizumab (Avastin)FDA Link 04/2014 - 07/2010
2	talazoparibIBA 11/2023 - 01/2020
2	Sunitinib (Sutent)FDA Link 01/2023 - 07/2012
2	cabozantinibIBA 01/2022 - 08/2014
2	tyrosine receptor (receptor, tyrosine)IBA 01/2022 - 12/2021
2	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 11/2020
2	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2018
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 01/2021
2	pembrolizumabIBA 01/2021 - 10/2018
2	MethyltransferasesIBA 01/2020 - 01/2019
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020 - 11/2011
2	TetrahydrouridineIBA 01/2020 - 01/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 06/2005
2	Immune Checkpoint InhibitorsIBA 01/2020 - 10/2018
2	Molecular Chaperones (Chaperone, Molecular)IBA 01/2018 - 08/2015
2	FenretinideIBA 08/2017 - 03/2011
2	Vorinostat FDA Link 05/2017 - 10/2010
2	Histones (Histone)IBA 07/2016 - 10/2015
2	Hypoxia-Inducible Factor 1IBA 11/2015 - 08/2011
2	Topoisomerase I InhibitorsIBA 11/2015 - 09/2011
2	olaparibIBA 11/2015 - 04/2012
2	Cetuximab (Erbitux)FDA Link 09/2015 - 09/2011
2	Alkylating AgentsIBA 03/2012 - 03/2005
2	PHY 906IBA 06/2011 - 02/2003
2	Insulin (Novolin)FDA Link 01/2010 - 05/2008
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2024
1	fms-Like Tyrosine Kinase 3IBA 01/2024

Therapy/Procedure

40	Therapeutics 12/2023 - 01/2006
8	Drug Therapy (Chemotherapy) 01/2023 - 02/2003
3	Immunotherapy 01/2020 - 06/2005
1	Neoadjuvant Therapy 01/2023
1	Prostatectomy (Retropubic Prostatectomy) 01/2022